Drug resistant immunotherapy for treatment of a cancer
OwnerH. Trent Spencer, Anindya Dasgupta +1inventors
InventorsH. Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.
Claims8
1-30. (canceled)
An isolated composition comprising γδ T-cells genetically engineered to express a polypeptide that confers resistance to a chemotherapy agent.
An isolated composition comprising γδ T-cells comprising a nucleic acid that encodes a polypeptide that confers resistance to a chemotherapy agent.
An isolated composition comprising natural killer cells wherein greater than about 50% of the natural killer cells express a polypeptide that confers resistance to a chemotherapy agent.
An isolated composition comprising natural killer cells wherein greater than about 50% of the natural killer cells comprise a nucleic acid that encodes a polypeptide that confers resistance to a chemotherapy agent.
An isolated composition consisting essentially of natural killer cells comprising a nucleic acid that encodes a polypeptide that confers resistance to a chemotherapy agent.
Dependencies are inferred from the claim text.